Pharmacokinetics of Trans ‐resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects
2009; Wiley; Volume: 49; Issue: 12 Linguagem: Inglês
10.1177/0091270009339191
ISSN1552-4604
AutoresTeresa Nunes, Luís Almeida, José‐Francisco Rocha, Amílcar Falcão, Carlos Fernandes‐Lopes, Ana I. Loureiro, Lyndon Wright, Manuel Vaz‐da‐Silva, Patrı́cio Soares-da-Silva,
Tópico(s)Adenosine and Purinergic Signaling
ResumoThe Journal of Clinical PharmacologyVolume 49, Issue 12 p. 1477-1482 Pharmacokinetics of Trans-resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects Dr Teresa Nunes MD, Dr Teresa Nunes MD Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr Luis Almeida MD, PhD, FFPM, Dr Luis Almeida MD, PhD, FFPM Department of Research and Development, S Mamede do Coronado, Portugal Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal Department of Health Sciences, University of Aveiro, PortugalSearch for more papers by this authorMr José-Francisco Rocha BSc, Mr José-Francisco Rocha BSc Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr Amílcar Falcão PharmD, PhD, Dr Amílcar Falcão PharmD, PhD 4Health Consulting, BIOCANT, Cantanhede, Portugal.Search for more papers by this authorMr Carlos Fernandes-Lopes BSc, Mr Carlos Fernandes-Lopes BSc Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorMs Ana I. Loureiro MSc, Ms Ana I. Loureiro MSc Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr Lyndon Wright PhD, Dr Lyndon Wright PhD Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr M. Vaz-da-Silva MD, PhD, Dr M. Vaz-da-Silva MD, PhD Department of Research and Development, S Mamede do Coronado, Portugal Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, PortugalSearch for more papers by this authorDr Patrício Soares-da-Silva MD, PhD, Corresponding Author Dr Patrício Soares-da-Silva MD, PhD Department of Research and Development, S Mamede do Coronado, Portugal Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal Address for correspondence: Patrício Soares-da-Silva, MD, PhD, Department of Research & Development, BIAL, À Av da Siderurgia Nacional, 4745–457 S Mamede do Coronado, Portugal; e-mail: [email protected].Search for more papers by this author Dr Teresa Nunes MD, Dr Teresa Nunes MD Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr Luis Almeida MD, PhD, FFPM, Dr Luis Almeida MD, PhD, FFPM Department of Research and Development, S Mamede do Coronado, Portugal Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal Department of Health Sciences, University of Aveiro, PortugalSearch for more papers by this authorMr José-Francisco Rocha BSc, Mr José-Francisco Rocha BSc Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr Amílcar Falcão PharmD, PhD, Dr Amílcar Falcão PharmD, PhD 4Health Consulting, BIOCANT, Cantanhede, Portugal.Search for more papers by this authorMr Carlos Fernandes-Lopes BSc, Mr Carlos Fernandes-Lopes BSc Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorMs Ana I. Loureiro MSc, Ms Ana I. Loureiro MSc Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr Lyndon Wright PhD, Dr Lyndon Wright PhD Department of Research and Development, S Mamede do Coronado, PortugalSearch for more papers by this authorDr M. Vaz-da-Silva MD, PhD, Dr M. Vaz-da-Silva MD, PhD Department of Research and Development, S Mamede do Coronado, Portugal Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, PortugalSearch for more papers by this authorDr Patrício Soares-da-Silva MD, PhD, Corresponding Author Dr Patrício Soares-da-Silva MD, PhD Department of Research and Development, S Mamede do Coronado, Portugal Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal Address for correspondence: Patrício Soares-da-Silva, MD, PhD, Department of Research & Development, BIAL, À Av da Siderurgia Nacional, 4745–457 S Mamede do Coronado, Portugal; e-mail: [email protected].Search for more papers by this author First published: 07 March 2013 https://doi.org/10.1177/0091270009339191Citations: 84Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005; 49(5): 405–430. 10.1002/mnfr.200500022 PubMedWeb of Science®Google Scholar 2 Fremont L. Biological effects of resveratrol. Life Sci. 2000; 66(8): 663–673. 10.1016/S0024-3205(99)00410-5 CASPubMedWeb of Science®Google Scholar 3 Bhat KPL, Kosmeder JW II, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001; 3(6): 1041–1064. 10.1089/152308601317203567 CASPubMedWeb of Science®Google Scholar 4 Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol. 1998; 138(6): 619–620. 10.1530/eje.0.1380619 CASPubMedWeb of Science®Google Scholar 5 Zhuang H, Kim YS, Koehler RC, Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci. 2003; 993: 276–286. 10.1111/j.1749-6632.2003.tb07534.x CASPubMedWeb of Science®Google Scholar 6 Bruno R, Ghisolfi L, Priulla M, Nicolin A, Bertelli A. Wine and tumors: study of resveratrol. Drugs Exp Clin Res. 2003; 29(5–6): 257–261. CASPubMedWeb of Science®Google Scholar 7 Aziz MH, Kumar R, Ahmad N. Cancer prevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms. Int J Oncol. 2003; 23: 17–28. CASPubMedWeb of Science®Google Scholar 8 Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo**-immunosensitizing activities. Curr Med Chem Anticancer Agents. 2003; 3(2): 77–93. 10.2174/1568011033353443 CASPubMedGoogle Scholar 9 Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets. 2006; 7(4): 423–442. 10.2174/138945006776359331 CASPubMedWeb of Science®Google Scholar 10 Anekonda TS. Resveratrol—a boon for treating Alzheimer's disease? Brain Res Rev. 2006; 52(2): 316–326. 10.1016/j.brainresrev.2006.04.004 CASPubMedWeb of Science®Google Scholar 11 Kumar A, Kaundal RK, Iyer S, Sharma SS. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 2007; 80(13): 1236–1244. 10.1016/j.lfs.2006.12.036 CASPubMedWeb of Science®Google Scholar 12 Palma PN, Bonifacio MJ, Almeida L, Soares-da-Silva P. Restoring dopamine levels. In: HJ Smith, C Simons, RDE Sewell, eds. Protein Misfolding in Neurodegenerative Diseases. Boca Raton, FL: CRC Press; 2008: 415–445. Web of Science®Google Scholar 13 Soares-da-Silva P. Patent WO 01/068065 A3. Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease. World Intellectual Property Organization; 2001. Google Scholar 14 Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord. 2008; 23(suppl 3): S580–S584. 10.1002/mds.22037 PubMedWeb of Science®Google Scholar 15 Chow S-C, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001; 28(2): 155–169. 10.1023/A:1011503032353 CASPubMedWeb of Science®Google Scholar 16 Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004; 32(12): 1377–1382. 10.1124/dmd.104.000885 CASPubMedWeb of Science®Google Scholar 17 Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005; 49(5): 472–481. 10.1002/mnfr.200500010 CASPubMedWeb of Science®Google Scholar 18 Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007; 16(6): 1246–1252. 10.1158/1055-9965.EPI-07-0022 CASPubMedWeb of Science®Google Scholar 19 Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009. In press. 10.1002/mnfr.200800177 PubMedWeb of Science®Google Scholar 20 Wang LX, Heredia A, Song H, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci. 2004; 93(10): 2448–2457. 10.1002/jps.20156 CASPubMedWeb of Science®Google Scholar Citing Literature Volume49, Issue12December 2009Pages 1477-1482 ReferencesRelatedInformation
Referência(s)